SECRET

Exploitation of the SECRETory pathway for cancer therapy to address European research

Funding period:

01.10.2019 - 31.09.2023

Project description:

The overall research objective of SECRET is to drive the understanding of the mutual regulation of the secretory pathway and signaling in breast and colorectal cancer, which will serve as a platform to identify and interrogate novel diagnostic and therapeutic strategies.

Partners

1. UNIVERSITETET I OSLO, PROBLEMVEIEN 5-7, 0313, OSLO, NO, in short UiO
2. UNIVERSITAETSKLINIKUM FREIBURG, HUGSTETTER STRASSE 49, 79106, FREIBURG, DE, in short UKFLR
3. CONSIGLIO NAZIONALE DELLE RICERCHE, PIAZZALE ALDO MORO 7, 00185, ROMA, IT, in short CNR
4. STICHTING VUMC, DE BOELELAAN 1117, 1081 HV, AMSTERDAM, NL, in short VUMC
5. MEDIZINISCHE UNIVERSITAET WIEN, SPITALGASSE 23, 1090, WIEN, AT, in short MUW
6. OSLO UNIVERSITETSSYKEHUS HF, KIRKEVEIEN 166 TARNBYGGET, 0450, OSLO, NO, in short OUH
7. TEL AVIV UNIVERSITY, registration number IL589931187, RAMAT AVIV, 69978, TEL AVIV, IL, in short TAU
8. ANAXOMICS BIOTECH, S.L., CALLE BALMES (PISO 4 - PTA 2A) 89, 08008, Barcelona, ES, in short AX
9. CHARLES RIVER DISCOVERY RESEARCH SERVICES GERMANY GMBH, AM FLUGHAFEN 12-14, 79108, FREIBURG, DE, in short CRDS
10. PROTATOUANS - ETAIREIA EREYNAS VIOTECHNOLOGIAS MONOPROSOPI ETAIREIA PERIORISMENIS EYTHINIS, ODOS NAVARCHOU VOTSI 3, 16675, GLYFADA, EL, in short PAO

 

Project coordination

 

Dr. Angelika Hausser

To the top of the page